Processing

Please wait...

PATENTSCOPE will be unavailable a few hours for maintenance reason on Monday 22.04.2024 at 12:00 PM CEST
Settings

Settings

Goto Application

Offices all Languages en Stemming true Single Family Member false Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

CHEM:(FBPFZTCFMRRESA-UHFFFAOYSA-N)

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1.104427984Use of substituted hexitols including dianhydrogalactitol and analogs to treat neoplastic disease and cancer stem cells including glioblastoma multforme and medulloblastoma
CN 18.03.2015
Int.Class A61K 31/35
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
335having oxygen as the only ring hetero atom, e.g. fungichromin
35having six-membered rings with one oxygen as the only ring hetero atom
Appl.No 201380015319.5 Applicant BROWN DENNIS Inventor BACHA JEFFREY
The use of dianhydrogalactitol provides a novel therapeutic modality for the treatment of glioblastoma multiforme and medulloblastoma. Dianhydrogalactitol acts as an alkylating agent on DNA that creates N7 methylation. Dianhydrogalactitol is effective in suppressing the growth of cancer stem cells and is active against tumors that are refractory to temozolomide; the drug acts independently of the MGMT repair mechanism.
2.1020160132130폐의 비소세포 암종 및 난소암을 치료하기 위한 디안하이드로갈락티톨 및 이의 유사체 또는 유도체
KR 16.11.2016
Int.Class A61K 31/336
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
335having oxygen as the only ring hetero atom, e.g. fungichromin
336having three-membered rings, e.g. oxirane, fumagillin
Appl.No 1020167030879 Applicant 델 마 파마슈티컬스 Inventor 바차, 제프리, 에이.
디안하이드로갈락티톨의 사용은 비소세포 폐암종(NSCLC) 및 난소암의 치료를 위한 새로운 치료 양식을 제공한다. 디안하이드로갈락티톨은 DNA에 N 메틸화를 생성하는 알킬화제로서 작용한다. 디안하이드로갈락티톨은 암 줄기세포의 성장을 억제하는데 유효하고, 테모졸로미드, 시스플라틴, 및 티미딘 키나제 저해제에 대해 난치성인 종양에 대하여 활성이 있다; 이 약물은 MGMT 복구 메커니즘와 독립적으로 작용한다. 디안하이드로갈락티톨 다른 항신생물제와 함께 사용될 수 있으며, 부가적 또는 초부가적 효과를 가질 수 있다. 7
3.1020160065776재발성 악성 신경교종 또는 진행성 2차 뇌종양의 치료를 위한 디안히드로갈락티톨 및 그의 유사체 및 유도체의 용도
KR 09.06.2016
Int.Class A61K 31/336
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
335having oxygen as the only ring hetero atom, e.g. fungichromin
336having three-membered rings, e.g. oxirane, fumagillin
Appl.No 1020157037286 Applicant 델 마 파마슈티컬스 인코포레이티드 Inventor 브라운, 데니스, 엠.
재발성 신경교종 및 진행성 2차 뇌종양과 같은 악성 종양의 치료에 적합한 방법 및 조성물이 개시된다. 이들 방법은 디안히드로갈락티톨, 디안히드로갈락티톨의 유도체 또는 유사체, 디아세틸디안히드로갈락티톨, 또는 디아세틸디안히드로갈락티톨의 유도체 또는 유사체와 같은 헥시톨 유도체를 사용한다. 조성물은 이러한 헥시톨 유도체를 포함할 수 있다.
4.20100009355SELECTIVE AMPLIFICATION OF MINORITY MUTATIONS USING PRIMER BLOCKING HIGH-AFFINITY OLIGONUCLEOTIDES
US 14.01.2010
Int.Class C12Q 1/68
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
68involving nucleic acids
Appl.No 12282504 Applicant Inventor Kolodney Michael S.

In certain embodiments this invention pertains to methods of detecting and/or quantifying rare mutant nucleic acids in populations of nucleic acids in which the wild-type nucleic acids are in substantially greater abundance than the rare mutants. In various embodiments the methods utilize short high affinity oligonucleotides targeted to the wild type rather than the minority or mutant sequence. Rather than directly detecting mutant DNA, these probes block detection of wild type DNA. These “blocker” probes can be used in combination with longer “detection” probes or PCR primers to amplify and/or identify the minority mutation in, e.g., clinical specimens. The combination of short high affinity blocker probes and longer, lower affinity detection probes eliminates the single base specificity/complexity tradeoff in the design of nucleic acid probes.

5.1020210100754재발성 악성 신경교종 또는 진행성 2차 뇌종양의 치료를 위한 디안히드로갈락티톨 및 그의 유사체 및 유도체의 용도
KR 17.08.2021
Int.Class A61K 31/336
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
335having oxygen as the only ring hetero atom, e.g. fungichromin
336having three-membered rings, e.g. oxirane, fumagillin
Appl.No 1020217025060 Applicant 델 마 파마슈티컬스 Inventor 브라운, 데니스, 엠.
재발성 신경교종 및 진행성 2차 뇌종양과 같은 악성 종양의 치료에 적합한 방법 및 조성물이 개시된다. 이들 방법은 디안히드로갈락티톨, 디안히드로갈락티톨의 유도체 또는 유사체, 디아세틸디안히드로갈락티톨, 또는 디아세틸디안히드로갈락티톨의 유도체 또는 유사체와 같은 헥시톨 유도체를 사용한다. 조성물은 이러한 헥시톨 유도체를 포함할 수 있다.
6.WO/1997/030064HEXITOL CONTAINING OLIGONUCLEOTIDES AND THEIR USE IN ANTISENSE STRATEGIES
WO 21.08.1997
Int.Class A61K 38/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
Appl.No PCT/EP1997/000762 Applicant STICHTING REGA VZW Inventor HERDEWIJN, Piet, André, Maurits, Maria
The present invention relates to novel oligomers comprising 1,5-anhydro-2,3-dideoxyhexitol nucleotide analogues and deoxyribose nucleotides. The invention further relates to complex consisting ofthe novel oligomer and a complementary single-stranded or double-stranded oligonucleotide. Pharmaceutical compositions, comprising the oligomer and/or the complex and the use of both in molecular biology and genetic engineering like hybridization, isolation of nucleic acids, site specific DNA modification and mapping.
7.2003038167CHROMOGENIC MEDIUM FOR DETECTING CARIOGENIC BACTERIUM
JP 12.02.2003
Int.Class C12N 1/20
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
1Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
20Bacteria; Culture media therefor
Appl.No 2001225137 Applicant EIKEN CHEM CO LTD Inventor KOJIMA TEI

PROBLEM TO BE SOLVED: To provide a medium capable of separately detecting Streptococcus mutans and Streptococcus sobrinus of the mutans streptococcus group which are pathogen of dental caries by distinguishing the colonies thereof by the colors.

SOLUTION: A specimen obtained from the oral cavity is cultured in the chromogenic medium for detecting the cariogenic bacteria, containing a - glycosidase-colored substrate, a hydrogen peroxide-colored chromogen, a peroxidase and a sugar alcohol to separately detect the Streptococcus mutans and the Streptococcus sobrinus.

COPYRIGHT: (C)2003,JPO

8.20230279501Bone Morphogenetic Protein-8B (BMP8B) as marker and therapeutic target for liver fibrosis or liver cancer
US 07.09.2023
Int.Class C12Q 1/6886
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
68involving nucleic acids
6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
6883for diseases caused by alterations of genetic material
6886for cancer
Appl.No 18011569 Applicant Friedrich-Alexander-Universität Erlangen-Nürnberg Inventor Claus HELLERBRAND

The present invention refers to BMP8B-inhibitor for use in a method of preventing and/or treating liver fibrosis and/or liver cancer, wherein the inhibitor is an oligonucleotide, an antibody or fragment thereof, a small molecule or a combination thereof. Further, the invention is directed to a method for diagnosing liver fibrosis and/or liver cancer and a kit for diagnosing fibrosis and/or cancer. The method and the kit can be used to identify a subject in need for a BMP8B-inhibitor to prevent and/or treat liver fibrosis and/or liver cancer.

9.20060166217Genetic marker for coronary artery disease
US 27.07.2006
Int.Class C12Q 1/68
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
68involving nucleic acids
Appl.No 10565263 Applicant AstraZeneca AB Inventor Carlsson Bjorn

The present invention describes a Coronary artery disease (CAD) susceptibility gene and the use of this gene in the development of novel therapies to treat CAD and in the diagnosis of susceptibility to CAD.

10.WO/2005/012564GENETIC MARKER FOR CORONARY ARTERY DISEASE
WO 10.02.2005
Int.Class C12Q 1/68
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
68involving nucleic acids
Appl.No PCT/GB2004/003153 Applicant ASTRAZENECA AB Inventor CARLSSON, Bjorn
ABSTRACT The present invention describes a Coronary artery disease (CAD) susceptibility gene and the use of this gene in the development of novel therapies to treat CAD and in the diagnosis of susceptibility to CAD.